Table 3.
Base-case outcomes for Model 1
| Outcome | UBT | mFAT | No retest |
|---|---|---|---|
| Economic outcomes per patient, US$ | |||
| Total costs | 325.76 | 242.12 | 182.41 |
| Tests | 102.81 | 19.70 | 0.00 |
| Physician visits | 146.88 | 146.88 | 0.00 |
| Second-line eradication | 20.63 | 22.28 | 0.00 |
| Excess lifetime costs | 55.45 | 53.26 | 182.41 |
| Incremental costs | |||
| Costs per accurately diagnosed case, US$ | 333.47 | 250.59 | 0.00 |
| ICER, US$/QALY gained vs no retest | 202.45 | 82.90 | – |
| Cost-effective vs no retest? | Y | Y | – |
| Health outcomes per patient | |||
| Cases accurately diagnosed as positive (n) | 0.18 | 0.18 | 0.00 |
| Cases accurately diagnosed as negative (n) | 0.80 | 0.79 | 0.00 |
| Reduced QALYs due to continuing H. pylori infection | 0.31 | 0.30 | 1.02 |
Abbreviations: ICER, incremental cost-effectiveness ratio; mFAT, monoclonal fecal antigen test; QALYs, quality-adjusted life-years; UBT, urea breath test; Y, yes; H. pylori, Helicobacter pylori.